leisure time -WSS

leisure time

author：fashion 2025-09-30 01:12:16 - browse：2

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

knowledge

WSS

What to know about Virgin Galactic's 1st mission taking paying customers to space

Senators: Long

How to use technology to prevent future drug shortages

Microbiome research is starting to find links to chronic diseases

CDC's new outbreak response network to include Northeastern

Police still searching for prisoner who escaped from NYC hospital

focus

leisure time

hotspot

Walensky prepares to leave CDC — and Congress — behind

Man killed during FBI raid in connection with threats against Biden, other officials

Activists slam private health insurers over coverage restrictions

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA panel to weigh approval of NurOwn, controversial ALS drug

At least 13 dead in Texas as scorching temps continue

FDA panel issues narrow recommendation for Covid vaccine booster doses

Hollywood unions extend contract negotiations for actors

Biotech stock slump in 2023: awaiting the turnaround

knowledge

What to know about Virgin Galactic's 1st mission taking paying customers to space

Ukraine and a new approach to mental health in war

South Korea throws huge K

Biotech stock slump in 2023: awaiting the turnaround

Microbiome research is starting to find links to chronic diseases

FDA panel issues narrow recommendation for Covid vaccine booster doses

entertainment

knowledge

knowledge

hotspot